We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves GSK’s Arnuity Ellipta to Treat Asthma
FDA Approves GSK’s Arnuity Ellipta to Treat Asthma
The FDA has cleared GlaxoSmithKline’s asthma drug Arnuity, adding a fourth product to GSK’s growing portfolio of respiratory drugs administered through its dry-powder inhaler Ellipta.